Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
研究单位：[1]BeiGene[2]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,233004[3]Beijing Cancer Hospital,Beijing,Beijing,China,100142[4]Peking Union Medical College Hospital - Oncology,Beijing,Beijing,China,100730[5]Cancer Hospital Chinese Academy of Medical Sciences City: Beijing,Beijing,Beijing,China[6]Peking University Third Hospital,Beijing,Beijing,China[7]Daping Hospital, Third Military Medical University,Chongqing,Chongqing,China,400042[8]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[9]Zhongshan Hospital,Fudan University (Xiamen Branch）,Xiamen,Fujian,China,361006[10]Mengchao Hepatobiliary Hospital of Fujian Medical University,Gulou,Fuzhou,China[11]The First Hospital of Lanzhou University,Lanzhou,Gansu,China,73000[12]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510000[13]Sun Yat-Sen University Cancer Center (Huangpu Campus),Guangzhou,Guangdong,China,510060[14]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510080[15]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,Guangzhou,Guangdong,China,510120[16]Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510515[17]Sun yat-sen memorial hospital, sun yat-sen university (south),Guanzhou,Guangdong,China,510275[18]The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China,530021[19]Guizhou Cancer Hospital,Guiyang,Guizhou,China,550000[20]Hainan General Hospital - Oncology,Haikou,Hainan,China[21]Second Affiliated Hospital of Zhejiang University School of Medicine,Zhejiang,Hangzhou,China,310009[22]Harbin Medical University Cancer Hospital - Oncology,Haerbin,Heilongjiang,China,150081[23]Hubei Cancer Hospital - Oncology,Wuhan,Hubei,China,400037[24]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China[25]Hunan Cancer Hospital,Changsha,Hunan,China,410013[26]The First People''s Hospital of Changzhou - Oncology,Changzhou,Jiangsu,China,213003[27]Nantong Tumor Hospital,Nantong,Jiangsu,China,226000[28]Affiliated hospital of Nantong university,Nantong,Jiangsu,China,226001[29]Northern Jiangsu people''s hospital - Oncology,Yangzhou,Jiangsu,China,225001[30]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[31]Jiangxi Province Cancer Hospital,Nanchang,Jiangxi,China,330039[32]The First Hospital of China Medical University,Shenyang,Liaoning,China,110001[33]Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology,Shenyang,Liaoning,China,110017[34]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China,110022[35]The Second Affiliated Hospital of Fujian Medical University,Fujian,Quanzhou,China,362001[36]Shandong Cancer Hospital - oncology - Oncology,Jinan,Shandong,China[37]The Affiliated Hospital of Qingdao University Branch South,Qingdao,Shandong,China,266000[38]Affiliated Zhongshan Hospital of Fudan University,Shanghai,Shanghai,China,200032[39]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,030013[40]Sichuan Cancer Hospital & Institute,Chengdu,Sichuan,China,610041[41]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610041[42]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China[43]Affiliated Cancer Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China[44]The First Affiliated Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China[45]Yunnan Cancer Hospital - Oncology,Kunming,Yunnan,China,650100[46]Yunnan Cancer Hospital, &The Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center &Yunnan Cancer Center,Kunming,Yunnan,China,650118[47]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[48]Taizhou Hospital of Zhejiang Province,Taizhou,Zhejiang,China,317000[49]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China[50]The First Affiliated Hospital of Chongqing Medical University,Chongqing,China[51]Zh
The purpose of this study is to compare the efficacy and safety of sitravatinib plus tislelizumab or placebo plus tislelizumab versus placebo. The study will also compare the recurrence-free survival (RFS) in participants with hepatocellular carcinoma (HCC) who are at high risk of recurrence after surgical resection.
